Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to add MASH to the label of its GLP-1 agonist semaglutide.The Danish pharma group is paying $54 per share in cash for Akero, with another $6 per share – […]
